Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity

Breast Cancer Research

Volumn 16, Issue 3, 2014, Pages

  Yokoyama, Yuhki ^a   Matsumoto, Ayaka ^a   Hieda, Miki ^a   Shinchi, Yoshimi ^a   Ogihara, Eri ^a   Hamada, Mai ^a   Nishioka, Yu ^a   Kimura, Hiroshi ^b   Yoshidome, Katsuhide ^c   Tsujimoto, Masahiko ^c   Matsuura, Nariaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H4; HISTONE H4K20ME3; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE METHYLTRANSFERASE; SUV420H1 PROTEIN; SUV420H2 PROTEIN; ERBB2 PROTEIN, HUMAN; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; SMALL INTERFERING RNA; SUV420H2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE OVEREXPRESSION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OVERALL SURVIVAL; PREDICTION; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; TUMOR INVASION; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; HISTONE H3 LYSINE 9 TRIMETHYLATION; HISTONE H4 LYSINE 20 TRIMETHYLATION; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; BIOSYNTHESIS; BREAST TUMOR; CANCER GRADING; FEMALE; GENETICS; METABOLISM; METHYLATION; MORTALITY; RNA INTERFERENCE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; METHYLATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84902739296     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3681     Document Type: Article

References (52)

1. Campbell LL, Polya K. Breast tumor heterogeneity, cancer stem cells or clonal evolution. Cell Cycle 2007, 6:2332-2338.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
5. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5:5-23.
6. Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 2011, 30:3391-3403.
7. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009, 15:3918-3926.
8. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011, 17:330-339.
9. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
10. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37:391-400.
11. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
12. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009, 174:1619-1628.
13. Behbahani TE, Kahl P, von der Gathen J, Heukamp LC, Baumann C, Gütgemann I, Walter B, Hofstädter F, Bastian PJ, von Ruecker A, Müller SC, Rogenhofer S, Ellinger J. Alterations of global histone H4K20 methylation during prostate carcinogenesis. BMC Urol 2012, 12:5.
14. Balakrishnan L, Mikavetz B. Decoding the histone H4 lysine 20 methylation mark. Crit Rev Biochem Mol Biol 2010, 45:440-452.
15. Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, Eymin B, Khochbin S, Gazzeri S. Loss of histone H4K20 Trimethylation occurs in preneoplasia and influences prognisis of non-small cell lung cancer. Clin Cancer Res 2008, 14:7237-7245.
16. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA, Pogribny IP. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle 2007, 6:2010-2018.
17. Tryndyak VP, Kovalchuk O, Pogribny IP. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20 h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 2006, 5:65-70.
18. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Colins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM, Ellis IO. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009, 69:3802-3809.
19. Yokoyama Y, Hieda M, Nishioka Y, Matsumoto A, Higashi S, Kimura H, Yamamoto H, Mori M, Matsuura S, Matsuura N. Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo. Cancer Sci 2013, 104:889-895.
20. Hayashi-Takanaka Y, Yamagata K, Wakayama T, Stasevich TJ, Kainuma T, Tsurimoto T, Tachibana M, Shinkai Y, Kurumizaka H, Nozaki N, Kimura H. Tracking epigenetic histone modifications in single cells using Fab-based live endogenous modification labeling. Nucleic Acids Res 2011, 39:6475-6488.
21. Chandra T, Kirschner K, Thuret JY, Pope BD, Ryba T, Newman S, Ahmed K, Samarajiwa SA, Salama R, Carroll T, Stark R, Janky R, Narita M, Xue L, Chicas A, Nũnez S, Janknecht R, Hayashi-Takanaka Y, Wilson MD, Marshall A, Odom DT, Babu MM, Bazett-Jones DP, Tavaré S, Edwards PA, Lowe SW, Kimura H, Gilbert DM, Narita M. Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. Mol Cell 2012, 47:203-214.
22. Shaker M, Yokoyama Y, Mori S, Tsujimoto M, Kawaguchi N, Kiyono T, Nakano T, Matsuura N. Aberrant expression of disintegrin-metalloprotease proteins in the formation and progression of uterine cervical cancer. Pathobiology 2011, 78:149-161.
23. Tanaka H, Nishioka Y, Yokoyama Y, Higashiyama S, Matsuura N, Matsuura S, Hieda M. Nuclear envelope-localized EGF family protein amphiregulin activates breast cancer cell migration in an EGF-like domain independent manner. Biochem Biophys Res Commun 2012, 420:721-726.
24. Sakamoto G, Inaji H, Akiyama F, Haga S, Hiraoka M, Inai K, Iwase T, Kobayashi S, Sakamoto G, Sano M, Sato T, Sonoo H, Tsuchiya S, Watanabe T, . Japanese Breast Cancer Society General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 2005, 12:S1-S27. Japanese Breast Cancer Society.
25. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Jenuwein T. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 2004, 18:1251-1262.
26. Kourmouli N, Jeppesen P, Mahadevhaiah S, Burgoyne P, Wu R, Gilbert DM, Bongiorni S, Prantera G, Fanti L, Pimpinelli S, Shi W, Fundele R, Singh PB. Heterochromatin and tri-methylated lysine 20 of histone H4 in animals. J Cell Sci 2004, 117:2491-2501.
27. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008, 15:1968-1976.
28. Song JS, Kim YS, Kim DK, Park SI, Jang SJ. Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients. Pathol Int 2012, 62:182-190.
29. MENT: methylation and expression database of normal and tumor tissues. [http://mgrc.kribb.re.kr:8080/MENT].
30. Baek SJ, Yang S, Kang TW, Park SM, Kim YS, Kim SY. MENT: methylation and expression database of normal and tumor tissues. Gene 2013, 518:194-200.
31. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res 2011, 13:215.
32. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, Sandelin K, Derossis A, Cody H, Foulkes WD. Is breast cancer the same disease in Asian and Western countries?. World J Surg 2010, 34:2308-2324.
33. Hahn M, Dambacher S, Dulev S, Kuznetsova AY, Eck S, Wörz S, Sadic D, Schulte M, Mallm JP, Maiser A, Debs P, von Melchner H, Leonhardt H, Schermelleh L, Rohr K, Rippe K, Storchova Z, Schotta G. Suv4-20 h2 mediates chromatin compaction and is important for cohesin recruitment to heterochromatin. Genes Dev 2013, 27:859-872.
34. Jørgensen S, Schotta G, Sørensen CS. Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Res 2013, 41:2797-2806.
35. Madsen MW, Briand P. Relationship between tumorigenicity, in vitro invasiveness, and plasminogen activator production of human breast cell lines. Eur J Cancer 1990, 26:793-797.
36. Kelly T, Yan Y, Osborne RL, Athota AB, Rozypal TL, Colclasure JC, Chu WS. Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis 1998, 16:501-512.
37. Gerlitz G, Bustin M. The role of chromatin structure in cell migration. Trends Cell Biol 2011, 21:6-11.
38. Gerlitz G, Livnat I, Ziv C, Yarden O, Bustin M, Reiner O. Migration cues induce chromatin alterations. Traffic 2007, 8:1521-1529.
39. Gerlitz G, Bustin M. Efficient cell migration requires global chromatin condensation. J Cell Sci 2010, 123:2207-2217.
40. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD, Chodosh LA. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002, 2:451-461.
41. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K, Steeg PS. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007, 67:4190-4198.
42. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997, 57:1199-1205.
43. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284.
44. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011, 17:2613-2618.
45. Pang J, Toy KA, Griffith KA, Awuah B, Quayson S, Newman LA, Kleer CG. Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression. Breast Cancer Res Treat 2012, 135:59-66.
46. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, Lai TC, Chang JS, Jan YH, Chien MH, Yang CJ, Huang MS, Hsiao M, Kuo ML. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010, 70:7830-7840.
47. Kapoor-Vazirani P, Kagey JD, Vertino PM. SUV420H2-mediated H4K20 trimethylation enforces RNA polymerase II promoter-proximal pausing by blocking hMOF-dependent H4K16 acetylation. Mol Cell Biol 2011, 31:1594-1609.
48. Stender JD, Pascual G, Liu W, Kaikkonen MU, Do K, Spann NJ, Boutros M, Perrimon N, Rosenfeld MG, Glass CK. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol Cell 2012, 48:28-38.
49. Henckel A, Nakabayashi K, Sanz LA, Feil R, Hata K, Arnaud P. Histone methylation is mechanistically linked to DNA methylation at imprinting control regions in mammals. Hum Mol Genet 2009, 18:3375-3383.
50. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009, 8:724-732.
51. Richon VM, Johnston D, Sneeringer CJ, Jin L, Majer CR, Elliston K, Jerva LF, Scott MP, Copeland RA. Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des 2011, 78:199-210.
52. Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 2012, 4:1439-1460.